Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanomaJoel Ho, Rodabe N. Amaria, Adi Diab et al.|Frontiers in Oncology|2022Cited by 55
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated CancersVan K. Morris, Michael Frumovitz, Amir A. Jazaeri et al.|The Oncologist|2023Cited by 29
Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers.Van K. Morris, Amir A. Jazaeri, Shannon N. Westin et al.|Journal of Clinical Oncology|2021Cited by 8